Publication
Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (7)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 7
- cancerTransitional Cell Carcinomacivic_curation1.00
- drugAnti-PD-1 Monoclonal Antibody MEDI0680civic_curation1.00
- drugDurvalumabcivic_curation1.00
- geneMSH2civic_curation1.00
- geneMSH6civic_curation1.00
- variantMSH2 Losscivic_curation1.00
- variantMSH6 LOSScivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26674132
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MSH2 Loss1 | ||||||||
| Anti-PD-1 Monoclonal Antibody MEDI0680 + DurvalumabCombination | Transitional Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1877Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel… (full text at CIViC) PMID 26674132 · Castro et al., 2015 · Open in CIViC | civic |
| MSH6 LOSS1 | ||||||||
| Anti-PD-1 Monoclonal Antibody MEDI0680 + DurvalumabCombination | Transitional Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1878Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel… (full text at CIViC) PMID 26674132 · Castro et al., 2015 · Open in CIViC | civic |